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were driven by the lower costs of oral administration relative to subcutaneous injection 
and a lower rate of long-term complications. A number of one-way sensitivity analyses 
showed that the model was robust. CONCLUSIONS: Rivaroxaban dominates enoxa-
parin as prophylaxis against VTE following THR and TKR in Korea, reducing overall
costs and improving health outcomes.
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OBJECTIVES: To evaluate the cost-effectiveness of dabigatran etexilate (DGB) com-
pared to enoxaparin in the prevention of venous thromboembolism (VTE) following 
total hip replacement (THR) or total knee replacement (TKR) from the perspective of 
the Portuguese NHS. METHODS: DBG (220 mg once daily) was compared to enoxa-
parin (40 mg once daily) in patients undergoing THR (prophylaxis 28–35 days) and
TKR (6–10 days). A decision tree was used to model the ten week post-surgery acute
phase. A Markov process modeled long-term events such as recurrent VTE, post-
thrombotic syndrome and intracranial hemorrhage for patient’s remaining lifetimes. 
Relative risks for VTE and bleed events were derived from the DBG phase III trials, 
RE-NOVATE and RE-MODEL which compared DBG with enoxaparin 40 mg once
daily. Published longitudinal studies were used to estimate the probabilities of long-
term events. Resource use associated with administration of the prophylaxis and the 
management of clinical events was obtained from a national multi-centre prospective 
study involving 50 patients. Unit costs were taken from national sources. Utility
weights were taken from published international literature. RESULTS: VTE and bleed-
ing rates were similar for DBG and enoxaparin. DBG was marginally more expensive 
than enoxaparin in TKR but less costly in THR, since no nursing time for administra-
tion of treatment is required in hospital or following discharge. The probabilistic 
analysis estimated that DBG cost an additional €11 per patient in TKR (ICER €2,848 
/QALY) and saved €255 per patient in THR. The probability of DBG being cost-
effective was 79% in TKR and 99% in THR at a willingness to pay threshold of 
€20,000 per QALY. Results proved to be robust across a wide range of sensitivity 
analyses. CONCLUSIONS: DBG is cost-saving in THR compared to enoxaparin and 
non-inferior in terms of efﬁ cacy or safety. Thus, DBG is cost-effective for the preven-
tion of VTE in patients undergoing THR.
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OBJECTIVES: Atrial Fibrillaion (AF) is a major cause factor for stroke with signiﬁ cant 
burden on Health care system and individuals and “silent” (asymptomatic) AF
episodes are challenging to diagnose. Current diagnostic procedures (Holter-
Monitoring, ECG) alongside clinical evaluation under-detect AF in post-radiofre-
quency catheter ablation (RCA) patients because of the relatively short monitoring
period. The Insertable Cardiac Monitor (ICM) is a programmable monitoring system
that continuously monitors the patient and detects and store arrhythmia events and 
related diagnostic information. The major beneﬁ t to patients is the potential to dis-
continue oral anti-coagulations (OAC) if AF can be convincingly shown to have been
cured. This study assesses the cost-effectiveness of ICM in post RCA patients in the 
Canadian health care context. METHODS: A Markov model was developed to assess
the cost-effectiveness of standard medical care compared to ICM use from a Canadian
provider perspective. The time horizon was three years (four Markov Cycles). The 
main outcome was detecting asymptomatic episodes of AF, which was derived from 
published literature. The frequency of resources used (i.e., risk of stroke and utility 
scores) and associated costs were derived from literature and the Ontario Health
Insurance Policy. RESULTS: The incremental cost-effectiveness ratio (ICER) within 
four Markov cycles was $19,660/QALY which was well below the $50,000 accept-
ability threshold indicating that ICM is cost-effective in post RCA patients. Probabi-
listic sensitivity analysis showed model sensitivity to the QoL gain. However, at 95%
CI the model was still within the acceptability range (0.162–0.24) $19,660$52,730/
QALY. CONCLUSIONS: ICM is a safe, accurate and useful device for detecting 
asymptomatic AF in post-ablation patients. The cost of ICM is partially offset by 
savings in hospital setting due to potential savings from discontinuation of OACs and
costly adverse events. A societal perspective will reduce the ICER in favour of ICM 
by an increase in patients HRQoL.
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OBJECTIVES: Cost-effectiveness analyses of new treatments for cardiovascular 
disease frequently require input parameters whose values are known with uncertainty 
due to limited data. The objective of this paper is to determine the extent to which
published sensitivity analyses adhere to Health Technology Assessment (HTA) guide-
lines. METHODS: We performed a systematic review of published cost-effectiveness 
analyses for an example drug treatment scenario, dual oral antiplatelet therapy com-
pared with aspirin alone following acute coronary syndromes (ACS) and/or percutane-
ous coronary intervention (PCI). We searched for articles published in English from 
1997 to mid-2008 in PubMed, Cochrane Collaboration, EMBASE, and Health Eco-
nomic Evaluation Database (HEED). A total of 216 articles were identiﬁ ed: PubMed,
40; Cochrane, 27; EMBASE, 114; HEED, 35. Of these, 106 articles were unique, and 
16 were included in this review; all selected articles compared clopidogrel plus aspirin 
versus aspirin alone for patients with ACS and planned PCI. We created evidence 
tables to show the sensitivity of the cost-effectiveness estimates to changes in the input 
parameter values, as well as the data sources used for the reference-case and alternative 
estimates for different input parameter values. We also examined the extent to which 
the sensitivity analyses adhered to HTA guidelines. RESULTS: Cost-effectiveness ratios 
were most sensitive to changes in the efﬁ cacy of dual antiplatelet therapy and refer-
ence-case model assumptions about costs beyond the trial period. Although the alter-
native values tested in the sensitivity analysis for some input parameters were based 
on observed ranges or distributions, the alternative values tested for many other input 
parameters were assumed without justiﬁ cation. CONCLUSIONS: The sensitivity 
analyses of the cost-effectiveness studies of dual oral antiplatelet therapy were not 
fully adherent with HTA guidelines. In particular, long-term costs and beneﬁ ts were 
not always included in the reference case and justiﬁ cation of the alternative parameter 
values was not always provided.
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OBJECTIVES: To evaluate the incremental cost-effectiveness of four angiotensin 
receptor blockers in hypertension, in a large US managed care setting. METHODS:
A decision analytical model was developed to estimate costs to reach JNC-7 blood
pressure (BP) goal for four ARBs: olmesartan (OLM), valsartan (VAL), irbesartan
(IRB), and losartan (LOS). The study period was 5/1/01 to 12/31/06. Patients were 
q18 years, have q2 claims for the Index ARB, a medical claim for HTN (ICD-9 codes
401.xx-404.xx), and minimum 6 months pre- and 9 months post-index eligibility. 
Outcomes were all-cause and HTN-attributable actual plan costs to achieve JNC 7 
goal (140/90, 130/80 with diabetes mellitus, DM). Costs were calculated for over 
120,000 eligible patients receiving ARBs in the plan. BP goal attainment was deter-
mined from 1293 medical charts and linked to costs in the claims database. Model 
robustness was tested using Monte Carlo simulation and probabilistic sensitivity 
analysis (PSA). RESULTS: 121,472 patients met inclusion criteria. Mean age was 55.2 
years, 22 % had DM. ARB cohorts were (n) OLM (19,525); VAL (59,176); IRB 
(17,226) and LOS (25,546). OLM was found more effective in achieving JNC 7 goal, 
and to incur lower all-cause and HTN-attributable costs, dominating other options. 
The CE ratios per percent of patients to reach HTN goal for OLM were $8,964 (all-
cause costs) and $2,704 (HTN-attributable costs), compared to the ratios for LOS 
($10,848 and $3,291), VAL ($10,557 and $3,577) and IRB ($13,397 and $4325). (All
costs adjusted to 2006 CPI). Monte Carlo and PSA results were consistent with the
baseline analysis. CONCLUSIONS: Compared to VAL, IRB and LOS, OLM was
found to be the most cost-effective of the four ARBs for the treatment of hypertension 
in a large US managed care population.
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OBJECTIVES: To estimate cost-effectiveness of either the public health strategy of 
increasing tobacco taxes or implementing smoking bans in public venues as a strategy 
for anti-tobacco use. METHODS: Quit and mortality rates for smokers and nonsmok-
ers were obtained from extant published literature and incorporated into a Markov 
Chain Monte Carlo model. The model included the public policies of taxes or bans 
accounting for the incidence of acute myocardial infarction (AMI) and related mortal-
ity. The model incorporated the value of statistical life, and medical costs associated 
with AMI. RESULTS: The expected life years under conditions of taxes, bans, or
neither (base case) were similar at 60.23, 60.25, and 60.37 per smoker respectively. 
Implementation of bans resulted in net societal losses of $1476 and taxes $984 per 
smoker over the “no policy” condition. Costs were lowest under the strategy of 
